ASKA Pharmaceutical Holdings Co.,Ltd.
[Asuka Pharmaceutical] Transition to the Corporate Auditor Committee and Revision of Director Compensation System | May 2026
Asuka Pharmaceutical has decided to transition to a company with a Corporate Auditor Committee, revising the director compensation system and introducing a system for outside directors. The revision is subject to shareholder approval, reviewing compensation amounts and stock grant conditions to strengthen incentives for corporate value enhancement and promote value sharing with shareholders.
Key Figures
- Total reward upper limit: within 140 million yen per year (combined for tenure-based and performance-based systems)
- Stock grant upper limit: 140,000 shares per year (70,000 shares for tenure-based, 70,000 shares for performance-based)
- Target directors: all directors and outside directors to implement the system
AI要約
Outline of the System Revision
Asuka Pharmaceutical has reviewed its director compensation system in conjunction with transitioning to a company with a Corporate Auditor Committee. The revision includes partial modifications to the stock reward system with transfer restrictions for targeted directors and the introduction of a new performance-linked compensation system. This aims to enhance incentives for directors to improve corporate value and promote value sharing with shareholders. The system revision requires shareholder approval at the general meeting, with upper limits set for compensation amounts and stock grants.
System Implementation and Future Outlook
By introducing the new system, conditions for director compensation and stock grants are expected to become clearer, with increased linkage to performance. Similar systems will be introduced for outside directors to strengthen management oversight functions. These measures are aimed at sustainable corporate value improvement and maximizing shareholder value, positioned as part of future management strategies.
Asuka Pharmaceutical Holdings Inc.
Company overview · Stock price · Financial data · All IR
